EP0950060A4 - Inhibition antisens de molecules d'adhesion humaines - Google Patents

Inhibition antisens de molecules d'adhesion humaines

Info

Publication number
EP0950060A4
EP0950060A4 EP96945380A EP96945380A EP0950060A4 EP 0950060 A4 EP0950060 A4 EP 0950060A4 EP 96945380 A EP96945380 A EP 96945380A EP 96945380 A EP96945380 A EP 96945380A EP 0950060 A4 EP0950060 A4 EP 0950060A4
Authority
EP
European Patent Office
Prior art keywords
adhesion molecules
antisense inhibition
human adhesion
human
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96945380A
Other languages
German (de)
English (en)
Other versions
EP0950060A1 (fr
Inventor
Glenn D Hoke
Matthews O Bradley
Taffy J Williams
Che-Hung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyad Pharmaceutical Corp
Original Assignee
Dyad Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyad Pharmaceutical Corp filed Critical Dyad Pharmaceutical Corp
Publication of EP0950060A1 publication Critical patent/EP0950060A1/fr
Publication of EP0950060A4 publication Critical patent/EP0950060A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96945380A 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines Withdrawn EP0950060A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/019194 WO1998024797A1 (fr) 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines

Publications (2)

Publication Number Publication Date
EP0950060A1 EP0950060A1 (fr) 1999-10-20
EP0950060A4 true EP0950060A4 (fr) 2000-07-05

Family

ID=22256225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96945380A Withdrawn EP0950060A4 (fr) 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines

Country Status (5)

Country Link
EP (1) EP0950060A4 (fr)
JP (1) JP2001505432A (fr)
AU (1) AU1564897A (fr)
CA (1) CA2273203A1 (fr)
WO (1) WO1998024797A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018907A2 (fr) * 1998-09-25 2000-04-06 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Sequences anti-sens destinees a l'inhibition de l'expression de la molecule d'adhesion icam-1
DE19844111A1 (de) * 1998-09-25 2000-04-20 Deutsches Krebsforsch Antisense-Sequenzen für die Hemmung der Expression des Adhäsionsmoleküls ICAM-1
US6114517A (en) * 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
ES2245638T3 (es) 1999-01-27 2006-01-16 Becker, David, Dr. Formulaciones que comprenden nucleotidos antisentido para conexinas.
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
DE10141443B4 (de) * 2001-08-23 2007-02-01 Christos C. Prof. Dr. Zouboulis Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne
DK1699924T3 (da) 2003-12-03 2019-10-21 Ocunexus Therapeutics Inc Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume
KR20080031154A (ko) 2005-02-03 2008-04-08 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
CN101965193A (zh) 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
US8063023B2 (en) 2006-12-11 2011-11-22 Coda Therapeuctics, Inc. Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
EP3183346A4 (fr) 2014-08-22 2018-10-24 Auckland Uniservices Limited Modulateurs de canaux
US11466069B2 (en) 2017-04-28 2022-10-11 Auckland Uniservices Limited Methods of treatment and novel constructs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994022488A1 (fr) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. OLIGONUCLEOTIDES ANTISENS INTERFERANT AVEC L'ACTIVITE DE COIFFE DE L'ARNm ET INHIBANT LA TRADUCTION
WO1996015780A1 (fr) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions et procedes destines a la prevention et au traitement du rejet d'allogreffes
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
CA2082411A1 (fr) * 1991-06-28 1992-12-29 Robert D. Rosenberg Traitement localise aux oligonucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
WO1994022488A1 (fr) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. OLIGONUCLEOTIDES ANTISENS INTERFERANT AVEC L'ACTIVITE DE COIFFE DE L'ARNm ET INHIBANT LA TRADUCTION
WO1996015780A1 (fr) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions et procedes destines a la prevention et au traitement du rejet d'allogreffes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENNETT C F ET AL: "INHIBITION OF ICAM-1, VCAM-1 AND E-SELECTIN EXPRESSION WITH ANTISENSE OLIGONUCLEOTIDES", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, 9 January 1993 (1993-01-09), pages 354, XP000647853 *
LEE CH. ET AL.: "Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells.", SHOCK 1995 JUL;4(1):1-10, XP000892942 *
See also references of WO9824797A1 *

Also Published As

Publication number Publication date
CA2273203A1 (fr) 1998-06-11
EP0950060A1 (fr) 1999-10-20
AU1564897A (en) 1998-06-29
JP2001505432A (ja) 2001-04-24
WO1998024797A1 (fr) 1998-06-11

Similar Documents

Publication Publication Date Title
EG21382A (en) Treatment of water
PL329875A1 (en) Derivatives of carbolin
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
PL327569A1 (en) Promedications of thrombosin inhibitors
EP1009860A4 (fr) Inhibition du gene ras a l'aide d'oligonucleotides antisens
GB9526560D0 (en) Use of 2-Amino-Heterocycles
EP0950060A4 (fr) Inhibition antisens de molecules d'adhesion humaines
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
IL113992A0 (en) Use of copolymer-1
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
GB9615159D0 (en) Treatment of liquid
ZA969429B (en) Amidinohydrazones of ketones
GB2328397B (en) Manufacture of elongate members
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
ZA971958B (en) Treatment of cocoa
AU6920898A (en) Antisense inhibition of human stat-6
AU6578298A (en) Antisense inhibition of angiogenin expression
GB9611315D0 (en) Treatment of painted surfaces
ZA976333B (en) Treatment of obesity
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9724088D0 (en) Treatment of dyskinesia
GB9612603D0 (en) Treatment of biosolids
PL105402U1 (en) Hardware of line stand-isolator
ZA9811524B (en) Treatment of effluent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040716